Bristol Myers Squibb Reports Fourth Quarter and Full-Year Fi

Results Reflect Continued Strength of In-Line and New Products, Pipeline Execution and Business Development Activity, Supporting Growth Momentum into 2024  



Reports Fourth Quarter Revenues of...

Related Keywords

Japan , China , United States , Russia , Canada , Ukraine , Puerto Rico , Russian Federation , Japanese , Bristol Myers Squibb , Pomalyst Imnovid , Christopher Boerner , Mead Johnson , Twitter , Exchange Commission , Drug Administration , Business Development , Karuna Therapeutics Inc , Committee For Medicinal Products Human Use , European Commission , Linkedin , Youtube , Japan Ministry Of Health , B Drug Pricing Program , Mirati Therapeutics Inc , Rayzebio Inc , Instagram , Facebook , European Union , Securities Exchange , European Medicines Agency , International Intl , Bristol Myers Squibb Patient Assistance Foundation , International Metastatic Renal Cell Carcinoma Database Consortium , Bristol Myers , Licensing Income Net Impact , Myers Squibb , New Product , Biologics License Applications , Priority Review , Prescription Drug User Fee Act , Blinded Independent Central Review , Medicinal Products , Human Use , Japanese Phase , New Drug Application , Ended December , Karuna Therapeutics , Mirati Therapeutics , Statement Regarding Forward Looking , Legacy Portfolio , Growth Portfolio , Accepted Accounting Principles , Nimbus Therapeutics , Securities Act , Securities Exchange Act , Drug Pricing Program , Russian Federation Ukraine , Annual Report , Quarterly Reports , Current Reports , Income Taxes , Earnings Attributable , Average Common Shares Outstanding , Common Share , Months Ended December , In Line Products , Specified Items , Markets ,